RPRX insider transaction filings
Royalty Pharma plc — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-19. Screen RPRX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Hite Christopher — EVP & Chairman, Partnering | Sale (S): 100,000 @ $59.97 · Gift (G): 16,800 @ $0 | EDGAR |
| 2026-08-17 | 4 | Coyne Terrance P. — EVP & CFO | Sale (S): 9,230 @ $58.59 · Sale (S): 1,772 @ $59.14 | EDGAR |
| 2026-08-07 | 4 | Coyne Terrance P. — EVP & CFO | Grant/award (A): 11,002 @ $0 · Gift (G): 18,500 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Legorreta Pablo G. — CEO, Chairman of the Board, Director | Grant/award (A): 65,216 @ $0 · Gift (G): 30,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Urist Marshall — EVP, Research & Investments | Grant/award (A): 8,252 @ $0 · Gift (G): 3,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Hite Christopher — EVP & Chairman, Partnering | Grant/award (A): 11,002 @ $0 | EDGAR |
| 2026-07-02 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 9,099 @ $55.88 | EDGAR |
| 2026-07-02 | 4 | Hite Christopher — EVP & Chairman, Partnering | Sale (S): 97,446 @ $56.50 · Sale (S): 2,554 @ $57.10 · Sale (S): 29,400 @ $56.44 · Sale (S): 600 @ $57.09 | EDGAR |
| 2026-06-30 | 4 | Bassler Bonnie L — Director | Grant/award (A): 689 @ $54.40 | EDGAR |
| 2026-06-25 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 9,098 @ $55.18 | EDGAR |
| 2026-06-25 | 4 | Hite Christopher — EVP & Chairman, Partnering | Sale (S): 32,408 @ $54.11 · Sale (S): 117,592 @ $54.47 | EDGAR |
| 2026-06-08 | 4 | Engelbert Catherine M. — Director | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-06-08 | 4 | Ho Carole — Director | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-06-08 | 4 | Coric Vlad — Director | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-06-08 | 4 | Bassler Bonnie L — Director | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-06-08 | 4 | Norden Gregory — Director | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-06-08 | 4 | HODGSON DAVID C — Director | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-06-08 | 4 | LOVE TED W — Director | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-06-08 | 4 | WEATHERMAN ELIZABETH H — Director | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-05-28 | 4 | Coyne Terrance P. — EVP & CFO | Sale (S): 64,399 @ $53.98 | EDGAR |
| 2026-05-21 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 13,684 @ $52.75 | EDGAR |
| 2026-05-15 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 13,684 @ $53.06 | EDGAR |
| 2026-05-15 | 4 | Norden Gregory — Director | Sale (S): 3,045 @ $53 | EDGAR |
| 2026-05-08 | 4 | Urist Marshall — EVP, Research & Investments | Grant/award (A): 18,197 @ $0 | EDGAR |
| 2026-05-08 | 4 | Coyne Terrance P. — EVP & CFO | Grant/award (A): 24,263 @ $0 | EDGAR |
| 2026-05-08 | 4 | Hite Christopher — EVP & Vice Chairman | Grant/award (A): 24,263 @ $0 | EDGAR |
| 2026-05-08 | 4 | Legorreta Pablo G. — CEO, Chairman of the Board, Director | Grant/award (A): 143,821 @ $0 | EDGAR |
| 2026-04-30 | 4 | Coyne Terrance P. — EVP & CFO | Sale (S): 32,916 @ $49.78 · Sale (S): 1,875 @ $49.78 | EDGAR |
| 2026-04-02 | 4 | Coyne Terrance P. — EVP & CFO | Sale (S): 1,875 @ $48.33 · Sale (S): 32,916 @ $48.33 | EDGAR |
| 2026-03-31 | 4 | Bassler Bonnie L — Director | Grant/award (A): 815 @ $45.98 | EDGAR |
| 2026-03-25 | 4 | Coyne Terrance P. — EVP & CFO | Sale (S): 32,916 @ $45.53 · Sale (S): 1,875 @ $45.53 | EDGAR |
| 2026-03-04 | 4 | Coyne Terrance P. — EVP & CFO | Sale (S): 22,487 @ $46.67 · Sale (S): 10,429 @ $47.01 · Sale (S): 1,292 @ $46.67 · Sale (S): 583 @ $47.01 | EDGAR |
| 2026-02-25 | 4 | Coyne Terrance P. — EVP & CFO | Sale (S): 32,916 @ $45.32 · Sale (S): 1,875 @ $45.32 | EDGAR |
| 2026-02-13 | 4 | Urist Marshall — EVP, Research & Investments | Grant/award (A): 19,970 @ $0 | EDGAR |
| 2026-02-13 | 4 | Coyne Terrance P. — EVP & CFO | Grant/award (A): 26,626 @ $0 | EDGAR |
| 2026-02-13 | 4 | Hite Christopher — EVP & Vice Chairman | Grant/award (A): 26,626 @ $0 | EDGAR |
| 2026-02-13 | 4 | Legorreta Pablo G. — CEO, Chairman of the Board, Director | Grant/award (A): 157,828 @ $0 | EDGAR |
| 2026-02-04 | 4 | Coyne Terrance P. — EVP & CFO | Sale (S): 102,581 @ $42.08 · Sale (S): 108,759 @ $42.84 · Sale (S): 19,076 @ $43.29 · Sale (S): 5,843 @ $42.08 · Sale (S): 6,195 @ $42.84 · Sale (S): 1,087 @ $43.29 | EDGAR |
| 2026-02-02 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 20,000 @ $41.09 | EDGAR |
| 2026-01-26 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 20,000 @ $40.26 | EDGAR |
| 2026-01-23 | 4 | Coyne Terrance P. — EVP & CFO | Sale (S): 65,832 @ $39.35 · Sale (S): 3,750 @ $39.35 | EDGAR |
| 2026-01-20 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 20,000 @ $39.52 | EDGAR |
| 2026-01-13 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 20,000 @ $40.78 | EDGAR |
| 2026-01-06 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 20,000 @ $38.48 | EDGAR |
| 2026-01-06 | 4 | Coyne Terrance P. — EVP & CFO | Sale (S): 65,832 @ $38.42 · Sale (S): 3,750 @ $38.42 | EDGAR |
| 2026-01-02 | 4 | Bassler Bonnie L — Director | Grant/award (A): 967 @ $38.74 | EDGAR |
| 2025-12-29 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 20,000 @ $39.32 | EDGAR |
| 2025-12-22 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 20,000 @ $38.38 | EDGAR |
| 2025-12-19 | 4 | Lloyd George W. — EVP, Investments & CLO | Sale (S): 79,346 @ $38.57 · Sale (S): 30,654 @ $38.50 | EDGAR |
| 2025-12-17 | 4 | Urist Marshall — EVP, Research & Investments | Sale (S): 20,000 @ $38.32 | EDGAR |
Recent 8-K events — Royalty Pharma plc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-02-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-12-22 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RPRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →